☰

Hannah Wingate, Ph.D. - Publications

Affiliations: 
2007 The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Cell Biology
Tree Info Grants Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Wingate HF, Keyomarsi K. Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All. Cancer Research. 83: 3165-3167. PMID 37779425 DOI: 10.1158/0008-5472.CAN-23-2608  0.571
2023 Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Cancer Research. PMID 37384539 DOI: 10.1158/0008-5472.CAN-23-0705  0.664
2023 Hunt KK, Suman VJ, Wingate HF, Leitch AM, Unzeitig G, Boughey JC, Meric-Bernstam F, Ellis MJ, Olson J. Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. Annals of Surgical Oncology. PMID 36653664 DOI: 10.1245/s10434-022-12972-5  0.328
2019 Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgery. PMID 31436549 DOI: 10.1097/Sla.0000000000003551  0.646
2013 Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. 34: 2244-52. PMID 23722650 DOI: 10.1093/Carcin/Bgt186  0.643
2013 Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Research : Bcr. 15: R3. PMID 23320734 DOI: 10.1186/Bcr3374  0.701
2012 Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. Plos Genetics. 8: e1002538. PMID 22479189 DOI: 10.1371/Journal.Pgen.1002538  0.72
2012 Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Research and Treatment. 132: 575-88. PMID 21695458 DOI: 10.1007/S10549-011-1638-4  0.726
2011 Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Therapy. 18: 510-9. PMID 21546925 DOI: 10.1038/Cgt.2011.20  0.704
2011 Biernacka A, Karakas C, Wingate H, Bondy M, Sahin A, Hunt K, Khandan K. P5-03-01: Cytoplasmic Cyclin E and P-CDK2 Expression in Triple Negative Breast Carcinomas Measured by Immunohistochemistry Correlates with Poor Outcome. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-03-01  0.551
2010 Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle (Georgetown, Tex.). 9: 1122-30. PMID 20237430 DOI: 10.4161/Cc.9.6.10990  0.711
2010 Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1179-90. PMID 20145171 DOI: 10.1158/1078-0432.Ccr-09-1787  0.755
2009 Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle (Georgetown, Tex.). 8: 1062-8. PMID 19305161 DOI: 10.4161/Cc.8.7.8119  0.728
2008 Mittendorf EA, Wingate H, Liu Y, Keyomarsi K, Hunt KK. QS287. HER2 Regulates Expression of Low Molecular Weight Cyclin E Isoforms in Breast Cancer Journal of Surgical Research. 144: 380-381. DOI: 10.1016/J.Jss.2007.12.538  0.683
2005 Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. The Journal of Biological Chemistry. 280: 15148-57. PMID 15708847 DOI: 10.1074/Jbc.M409789200  0.678
2004 Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Research. 64: 3198-208. PMID 15126360 DOI: 10.1158/0008-5472.Can-03-3672  0.715
2003 Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle (Georgetown, Tex.). 2: 461-6. PMID 12963845 DOI: 10.4161/Cc.2.5.464  0.722
Show low-probability matches.